FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer, by blocking a protein that fuels tumor growth in the vast majority of cases.

The US Food and Drug Administration has approved a treatment for pancreatic cancer that, in clinical trials, nearly doubled the overall survival time for patients.

FDA officials gave expedited approval to daraxonrasib, which blocks a mutated protein that fuels tumor growth

The FDA has approved a drug that could extend the life of patients with late-stage pancreatic cancer. CBS News' medical correspondent Dr. Céline Gounder has more.

In a late-stage study, RevMed’s Rasonque helped subjects live to 13 months, nearly twice as long as those who only received chemotherapy.

Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.

Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.

The FDA approved Rasonque for pancreatic cancer. Here is when the drug will be available, who qualifies and what it costs.

Pancreatic cancer has been notoriously difficult to target and treat. wildpixel/iStock via Getty Images Plus For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of

The Food and Drug Administration on Wednesday rubber-stamped a new drug to treat pancreatic cancer and substantially extend the lives of patients. The drug, daraxonrasib, is produced by Revolution Medicines and was approved for individuals with metastatic pancreatic cancer who did not see success with chemotherapy. Doc

FDA Approves Landmark Pancreatic Cancer Drug That's Shown To Improve Survival  HuffPost

The US Food and Drug Administration announced its approval for a drug that could double the survival time of some patients for a type of cancer that has, historically, been difficult to treat.

The US Food and Drug Administration announced its approval for a drug that could double the survival time of some patients for a type of cancer that has, historically, been difficult to treat.

On Wednesday, the U.S. Food and Drug Administration announced its approval of Rasonque, a new treatment option for people with pancreatic cancer.

The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial

The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.

The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer.  The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Ra

The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer.

Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval  Reuters

Pancreatic cancer is among the deadliest forms, largely because detection is difficult before malignancy spreads to other organs

The U.S. Food and Drug Administration (FDA) on Wednesday approved a groundbreaking new treatment for advanced pancreatic cancer that nearly doubled median survival in a clinical trial, marking what experts are calling one of the biggest advances against the deadly disease in decades. The drug, daraxonrasib, which will

The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer The US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of t

Patients taking the drug nearly doubled their survival time, with fewer severe side effects, in a study that randomly assigned them to receive the experimental treatment or more chemotherapy.

Daraxonrasib made headlines earlier this year when former US Sen. Ben Sasse, R-Neb., shared details about his experience with the drug — which left his skin bloody and “bubbling” but is giving him more time with his family.

WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called dara

Pancreatic cancer is considered one of the hardest to treat and most serious cancers

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer

FDA approves landmark pancreatic cancer drug that’s shown to improve survival  AP News

FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque  Forbes

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug  CNN

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease  WSJ

The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.

Sussex mum with breast cancer hails breakthrough drug for 'new lease of life' | ITV News  ITVX